Felip E, Massuti B, Alonso G, et al. Surgery (s) alone, preoperative (preop) paclitaxel/carboplatin (PC) chemotherapy followed by s, or s followed by adjuvant (adj) pc chemotherapy in early-stage non-small cell lung cancer (NSCLC): results of the natch multicenter randomized phase III trial. J Clin Oncol, 27: abstr 7500, 2009.
Douillard JY, Rosell R and De Lena M, et al. (2006). Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage Ib–IIIa non-small-cell lung cancer (adjuvant navelbine international trialist association [anita].): a randomised controlled trial. Lancet Oncol
Arriagada R, Bergman B and Dunant A, et al. (2004). Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. N Engl J Med
Scagliotti GV, Fossati R and Torri V et al. (2003). Randomized study of adjuvant chemotherapy for completely resected stage I, II, or IIIa non-small-cell lung cancer. J Natl Cancer Inst
Strauss GM, Herndon JE, 2nd, Maddaus MA, et al. Adjuvant paclitaxel plus carboplatin compared with observation in stage Ib non-small-cell lung cancer: CALGB 9633 with the cancer and leukemia group b, radiation therapy oncology group, and north central cancer treatment group study groups. J Clin Oncol 26: 5043–5051, 2008.
Winton T, Livingston R and Johnson D, et al. (2005). Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer. N Engl J Med
Pignon JP, Tribodet H and Scagliotti GV, et al. (2008). Lung adjuvant cisplatin evaluation: a pooled analysis by the lace collaborative group. J Clin Oncol
Le Chevalier T, Dunant A, Arriagada R, et al. Long-term results of the international adjuvant lung cancer trial (IALT) evaluation adjuvant cisplatin-based chemotherapy in resected non-small cell lung cancer (NSCLC). J Clin Oncol, 26: abstr 8044, 2008.
Vincent MD, Butts C, Seymour L, et al. Updated survival analysis of jbr.10: a randomized phase III trial of vinorelbine/cisplatin versus observation in completely resected stage Ib and II non-small cell lung cancer (NSCLC). J Clin Oncol, 27: abstr 7501, 2009.
Brodowicz T, Krzakowski M and Zwitter M, et al. (2006). Cisplatin and gemcitabine first-line chemotherapy followed by maintenance gemcitabine or best supportive care in advanced non-small cell lung cancer: a phase III trial. Lung Cancer
Fidias PM, Dakhil SR and Lyss AP, et al. (2009). Phase III study of immediate compared with delayed docetaxel after front-line therapy with gemcitabine plus carboplatin in advanced non-small-cell lung cancer. J Clin Oncol
Ciuleanu TE, Brodowicz T, Belani CP, et al. Maintenance pemetrexed plus best supportive care (bsc) vs. placebo plus bsc: a phase III study. J Clin Oncol, 26: abstr 8011, 2008.
Belani CP, Brodowicz T, Ciuleanu T, et al. Maintenance pemetrexed (PEM) plus best supportive care (BSC) vs. placebo (PLAC) plus bsc: a randomized phase III study in advanced non-small cell lung cancer (NSCLC). J Clin Oncol, 27: abstr CRA8000, 2009.
Scagliotti G, Hanna N and Fossella F, et al. (2009). The differential efficacy of pemetrexed according to nsclc histology: a review of two phase III studies. Oncologist
Capuzzo F, Ciuleanu T, Steimakh L, et al. Saturn: a double-blind, randomized, phase III study of maintenance erlotinib versus placebo following nonprogression with first-line platinum-based chemotherapy in patients with advanced nsclc. J Clin Oncol, 27: abstr 8001, 2009.
Miller VA, Das A, Rossi M. A randomized, double-blind, placebocontrolled, phase IIIb trial (ATLAS) comparing bevacizumab (b) therapy with or without erlotinib (e) after completion of chemotherapy with b for first-line treatment of locally advanced, recurrent, or metastatic non-small cell lung cancer (NSCLC). J Clin Oncol, 27: abstr LBA8002, 2009.
Scagliotti GV, Parikh P and Pawel J, et al. (2008). Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol
Mok T, Wu Y-L, Thongprasert S, et al. Phase III, randomised, open-label, first-line study of gefitinib vs. carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer (IPASS). Ann Oncol, 19: viii1-viii4 (LBA2), 2008.
Fukuoka M, Wu Y, Thongprasert S, et al. Biomarker analyses from a phase III, randomized, open-label, first-line study of gefitinib (g) vs. carboplatin/paclitaxel (c/p) in clinically selected patients (pts) with advanced non-small cell lung cancer (NSCLC) in asia (IPASS). J Clin Oncol, 27: abstr 8006, 2009.
Pirker R, Szczesna A, von Pawel J, et al. FLEX: a randomized multicenter, phase III study of cetuximab in combination with cisplatin/vinorelbine (CV) versus CV alone in the first-line treatment of patients with advanced non-small cell lung cancer (NSCLC). J Clin Oncol, 26: abstr 3, 2008.
O’Byrne KJ, Bondarenko I, Barrios C, et al. Molecular and clinical predictors of outcome for cetuximab in non-small cell lung cancer (NSCLC): data from the flex study. J Clin Oncol, 17: abstr 8007, 2009.
Khambata-Ford S, Harbison C, Woytowitz D, et al. K-ras mutation (mut), EGFR-related, and exploratory markers as response predictors of cetuximab in first-line advanced NSCLC: retrospective analyses of the bms099 trial. J Clin Oncol, 27: abstr 8021, 2009.
Pham D, Kris MG and Riely GJ, et al. (2006). Use of cigarette-smoking history to estimate the likelihood of mutations in epidermal growth factor receptor gene exons 19 and 21 in lung adenocarcinomas. J Clin Oncol
Lynch TJ, Bell DW and Sordella R, et al. (2004). Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med
Paez JG, Janne PA and Lee JC, et al. (2004). EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science
Rosell R, Moran T and Queralt C, et al. (2009). Screening for epidermal growth factor receptor mutations in lung cancer. N Engl J Med
Ramalingam SS, Maitland M, Frankel P, et al. Randomized, double-blind, placebo-controlled phase II study of carboplatin and paclitaxel with or without vorinostat, a histone deacetylase inhibitor (HDAC), for first-line therapy of advanced non-small cell lung cancer (NCI 7863). J Clin Oncol, 17: abstr 8004, 2009.
Traynor AM, Dubey S, Eickhoff JC, et al. Vorinostat (nsc# 701852) in patients with relapsed non-small cell lung cancer: a wisconsin oncology network phase II study. J Thorac Oncol, 4: 522–526, 2009.
Groen H, Hochstenbag MM, van Putten JW, et al. A randomized placebo-controlled phase III study of docetaxel/carboplatin with celecoxib in patients (pts) with advanced non-small cell lung cancer (nsclc): the nvalt-4 study. J Clin Oncol, 27: abstr 8005, 2009.
Altorki NK, Keresztes RS and Port JL, et al. (2003). Celecoxib, a selective cyclooxygenase-2 inhibitor, enhances the response to preoperative paclitaxel and carboplatin in early-stage non-small-cell lung cancer. J Clin Oncol
Herbst RS, Sun Y, Korfee S, et al. Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small cell lung cancer (NSCLC): a randomized, double-blind phase III trial (ZODIAC). J Clin Oncol, 27: abstr CRA8003, 2009.
De Boer R, Arrieta O, Gottfried M, et al. Vandetanib plus pemetrexed versus pemetrexed as second-line therapy in patients with advanced non-small cell lung cancer (NSCLC): a randomized, double-blind phase III trial (ZEAL). J Clin Oncol, 27: abstr 8010, 2009.
Natale RB, Thongprasert S, Greco FA, et al. Vandetanib versus erlotinib in patients with advanced non-small cell lung cancer (NSCLC) after failure of at least one prior cytotoxic chemotherapy: a randomized, double-blind phase III trial (ZEST). J Clin Oncol, 27: abstr 8009, 2009.